市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | IMMUNOTECH-B | - | - |
AIStockmoo 评分
-0.6
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.63 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| ANTENGENE-B | 3 B | - | - | 2.84 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
|
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 72.90% |
| 机构持股比例 | 6.41% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合